Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
01 01 2019
Historique:
received: 27 08 2018
accepted: 10 10 2018
pubmed: 20 10 2018
medline: 1 10 2019
entrez: 19 10 2018
Statut: epublish

Résumé

HIV-1-specific cytotoxic T-lymphocytes (CTLs) with strong abilities to suppress HIV-1 replication and recognize most circulating HIV-1 strains are candidates for effector T cells for cure treatment and prophylactic AIDS vaccine. Previous studies demonstrated that the existence of CTLs specific for 11 epitopes was significantly associated with good clinical outcomes in Japan, although CTLs specific for one of these epitopes select for escape mutations. However, it remains unknown whether the CTLs specific for the remaining 10 epitopes suppress HIV-1 replication

Identifiants

pubmed: 30333175
pii: JVI.01480-18
doi: 10.1128/JVI.01480-18
pmc: PMC6288335
pii:
doi:

Substances chimiques

AIDS Vaccines 0
Epitopes, T-Lymphocyte 0
HLA-A Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2018 American Society for Microbiology.

Références

EBioMedicine. 2016 Jun;8:217-229
pubmed: 27428432
Front Genet. 2015 Jan 22;5:478
pubmed: 25657656
Nature. 2004 Dec 9;432(7018):769-75
pubmed: 15592417
J Virol. 2007 Nov;81(22):12608-18
pubmed: 17728232
Nat Med. 2007 Jan;13(1):46-53
pubmed: 17173051
Eur J Immunol. 2012 Oct;42(10):2621-31
pubmed: 22740036
Sci Transl Med. 2017 Feb 15;9(377):
pubmed: 28202771
PLoS Pathog. 2010 May 27;6(5):e1000917
pubmed: 20523897
J Virol. 2017 Mar 29;91(8):
pubmed: 28179527
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
Sci Rep. 2016 Aug 02;6:30749
pubmed: 27480951
Cell Host Microbe. 2015 Feb 11;17(2):141-2
pubmed: 25674977
PLoS Pathog. 2014 Aug 14;10(8):e1004287
pubmed: 25122219
J Virol. 2001 Jul;75(14):6508-16
pubmed: 11413318
Immunity. 2008 Dec 19;29(6):1009-21
pubmed: 19062316
Tissue Antigens. 2010 Jun;75(6):701-11
pubmed: 20230525
Immunogenetics. 1995;41(2-3):165-8
pubmed: 7806292
J Exp Med. 2006 May 15;203(5):1357-69
pubmed: 16682496
EBioMedicine. 2017 Sep;23:52-58
pubmed: 28803740
Immunity. 2012 Mar 23;36(3):491-501
pubmed: 22406268
J Immunol. 1995 Nov 15;155(10):4749-56
pubmed: 7594476
J Virol. 2009 Mar;83(6):2743-55
pubmed: 19116253
Microbes Infect. 2011 Feb;13(2):160-6
pubmed: 20971209
J Infect Dis. 2017 Dec 12;216(11):1415-1424
pubmed: 28968792
Int J Immunogenet. 2007 Jun;34(3):201-8
pubmed: 17504510
Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):597-602
pubmed: 11136234
Science. 2014 Jul 11;345(6193):169-74
pubmed: 25013067
Int J Immunogenet. 2011 Dec;38(6):475-81
pubmed: 21816002
Tissue Antigens. 2008 Feb;71(2):127-34
pubmed: 18086267
Retrovirology. 2013 Dec 12;10:152
pubmed: 24330837
J Virol. 2013 Feb;87(4):2253-63
pubmed: 23236061
N Engl J Med. 2013 Nov 28;369(22):2083-92
pubmed: 24099601
PLoS Pathog. 2016 Apr 15;12(4):e1005545
pubmed: 27082643
Nat Med. 2004 Mar;10(3):282-9
pubmed: 14770175
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
J Virol. 2002 Aug;76(15):7535-43
pubmed: 12097566
J Virol. 2015 May;89(10):5330-9
pubmed: 25741000
Nat Immunol. 2012 Jun 10;13(7):691-700
pubmed: 22683743
J Virol. 2012 Oct;86(19):10870-2
pubmed: 22811530
J Infect Dis. 1999 Aug;180(2):359-68
pubmed: 10395850
J Virol. 2010 Jul;84(14):7018-28
pubmed: 20444904
Nat Immunol. 2002 Nov;3(11):1061-8
pubmed: 12368910
J Virol. 2010 Jul;84(14):7151-60
pubmed: 20410273
Lancet. 2008 Nov 29;372(9653):1881-1893
pubmed: 19012954
Nature. 2015 Jan 15;517(7534):381-5
pubmed: 25561180
J Clin Invest. 2018 Feb 1;128(2):876-889
pubmed: 29355843
J Virol. 2014 Nov;88(21):12793-801
pubmed: 25165102
Nat Med. 1999 May;5(5):518-25
pubmed: 10229228
Nat Med. 1997 Feb;3(2):212-7
pubmed: 9018241
Blood. 2011 Apr 7;117(14):3799-808
pubmed: 21289310
J Exp Med. 2007 Oct 1;204(10):2473-85
pubmed: 17893201
AIDS Res Hum Retroviruses. 2005 May;21(5):363-70
pubmed: 15929698
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81
pubmed: 17428922
Microbes Infect. 2013 Nov;15(13):874-86
pubmed: 23968885
J Immunol. 2005 Jan 1;174(1):36-40
pubmed: 15611225
J Virol. 2014 May;88(9):4764-75
pubmed: 24522911
J Immunol. 2010 May 1;184(9):5383-91
pubmed: 20363973
Nat Med. 2015 Feb;21(2):132-9
pubmed: 25599132
Immunogenetics. 2002 Mar;53(12):1009-19
pubmed: 11904677
J Virol. 2012 Feb;86(4):1971-81
pubmed: 22156528

Auteurs

Hayato Murakoshi (H)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.

Nozomi Kuse (N)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.

Tomohiro Akahoshi (T)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.

Yu Zhang (Y)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.

Takayuki Chikata (T)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.

Mohamed Ali Borghan (MA)

Department of Physiology and Biophysics, College of Medicine and Health Sciences, National University of Science and Technology, Sohar, Sultanate of Oman.

Hiroyuki Gatanaga (H)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.

Shinichi Oka (S)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.

Keiko Sakai (K)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan.

Masafumi Takiguchi (M)

Center for AIDS Research, Kumamoto University, Kumamoto, Japan masafumi@kumamoto-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH